Sarclisa® (isatuximab-irfc) – New indication
March 31, 2021 - Sanofi announced the FDA approval of Sarclisa (isatuximab-irfc), in combination with Kyprolis® (carfilzomib) and dexamethasone, for the treatment of relapsed or refractory multiple myeloma in adult patients who have received one to three prior lines of therapy.
Top